SpineGuard Names Pierre Guyot to Board of Directors

SpineGuard has appointed Pierre Guyot to its Board of Directors.

Guyot has served as CEO and board director of Mölnlycke Healthcare since 2007, helping develop the Swedish corporation’s growth and profitability. Over the last seven years, Mölnlycke has grown into a company with more than 1 billion euros in revenue.

“I am delighted that Pierre has accepted to join SpineGuard. Having worked with him at Boston Scientific for a number of years, I know he will bring us invaluable strategic guidance as we expand commercially and develop new clinical applications for our PediGuard technology platform,” said Pierre Jérôme, SpineGuard co-founder and CEO.

Earlier in his career, Mr. Guyot held executive management positions at Becton Dickinson, Johnson & Johnson, and Boston Scientific.

“I am very excited by the opportunity to join SpineGuard,” Guyot said. “I strongly believe the PediGuard technology platform offers multi-faceted benefits to both patients and health care practitioners. I look forward to adding value to the Board of Directors and contributing to the further successful development of the PediGuard platform.”

SpineGuard Board Chairman Alan Olsen said Guyot’s expertise and leadership would benefit both the company and it shareholders.

“We are very pleased to welcome a leader of Pierre Guyot’s caliber to the board of SpineGuard. Pierre’s track record on developing medical technology divisions and companies into dynamic growth businesses makes him an excellent addition to the SpineGuard board,” he said in a formal statement. “Pierre’s expertise and leadership will be incredibly beneficial to SpineGuard, our employees and our shareholders.”

Co-invented by Maurice Bourlion, Ph.D., Ciaran Bolger, M.D., Ph.D., and Alain Vanquaethem, biomedical engineer, SpineGuard’s signature product — PediGuard — is a handheld device capable of alerting surgeons to potential pedicular or vertebral breaches. Real-time feedback is provided via audio and visual signals. More than 27,000 procedures have been performed with PediGuard on all continents. Several studies published in peer-reviewed medical and scientific journals have demonstrated that PediGuard detects 98 percent of pedicle breaches, presents an average screw placement accuracy of 97 percent (vs. 92 percent on average for navigation), provides three-fold less pedicle perforations than with free-hand technique and a three-fold reduction in neuro-monitoring alarms. It also limits radiation exposure by 25 percent to 30 percent and decreases the time for pedicle screw placement by 15 percent.

Founded in 2009, SpineGuard has offices inSan Francisco,Calif., and Paris, France. The company has been listed on the New York Stock Exchange since April 29, 2013.